Luma Health competes with Hims and stands to benefit if you choose Luma Health. This comparison is written from a competitive position, aiming to represent Hims' current program accurately and fairly, including acknowledging its genuine strengths in brand recognition and platform scale.
Hims built one of the most recognizable brands in direct-to-consumer telehealth, and for several years its compounded semaglutide program was a genuinely competitive option in the GLP-1 market. That changed significantly in 2026. A public dispute with Novo Nordisk disrupted Hims' compounded semaglutide supply chain, and the resolution reshaped what Hims can actually offer new and existing patients. This guide walks through what happened, what Hims looks like today, and how it compares to a stable, flat-rate compounded alternative.
2026 Update: Hims' Compounded Semaglutide Program Has Changed
Hims' compounded semaglutide program was disrupted by a public dispute with Novo Nordisk in early 2026. The dispute was settled in March 2026, with Hims signing a direct supply deal and transitioning toward branded Wegovy/Ozempic (~$299/month self-pay). Compounded semaglutide availability going forward is uncertain or limited — verify directly at hims.com before enrolling. Separately, Hims discontinued compounded tirzepatide entirely, now selling brand Zepbound at approximately $1,899/month instead.
The Novo Nordisk Dispute: What Actually Happened
Understanding why Hims' program changed helps explain why the current offering looks so different from what many patients originally signed up for. In early 2026, Hims' relationship with Novo Nordisk — the manufacturer of brand-name Wegovy and Ozempic — became publicly contentious over Hims' continued marketing and prescribing of compounded semaglutide after regulatory shifts had narrowed the legal basis for that practice. The dispute played out publicly and created genuine uncertainty for patients mid-treatment about whether their medication supply would continue uninterrupted.
The dispute was resolved in March 2026 through a direct supply agreement between Hims and Novo Nordisk. As part of that resolution, Hims shifted its primary semaglutide offering toward the branded product — Wegovy or Ozempic — rather than continuing to lead with compounded semaglutide as its flagship offering. This is a meaningfully different business than the one many patients originally enrolled with, and it's worth understanding that the platform you're evaluating today may not resemble the platform reviewed in older articles or patient testimonials from 2024 or 2025. Reviews and comparisons written before March 2026 should generally be treated as historical rather than current.
Hims — What It Is and How It Currently Works
Hims is one of the largest direct-to-consumer telehealth platforms in the US. Its GLP-1 program underwent significant changes in 2026 — the transition away from compounded medications toward branded products materially changes the cost equation for patients who enrolled expecting compounded pricing. Confirm current compounded semaglutide availability and pricing directly at hims.com before assuming any of the historical dose-tier figures still apply. This confirmation step matters more here than with most providers, precisely because the program has changed so substantially in a short window — a figure you saw quoted even a few months ago may no longer reflect what you'd actually be offered today.
What This Means If You're Currently a Hims Patient
If you enrolled with Hims before 2026 expecting stable, ongoing compounded semaglutide access, it's worth checking your account directly and asking Hims support three specific questions rather than assuming your situation is unaffected. First, ask whether your specific prescription is still being fulfilled as compounded semaglutide, or whether you've been transitioned to brand Wegovy or Ozempic without necessarily realizing it. Second, ask what your actual current monthly charge is — the ~$299/month self-pay figure applies to the branded transition, and if you're paying meaningfully more or less, get clarity on why. Third, ask directly whether Hims can commit to continued compounded access going forward, or whether your account will eventually be moved to the branded pathway regardless of your preference.
Patients who specifically want to continue with compounded medication — whether for cost reasons or because they've tolerated it well — may find that Hims' current direction doesn't reliably support that preference long-term. This is a reasonable point to evaluate switching to a platform where compounded semaglutide remains the stable, primary offering rather than a legacy option being phased out. Making that decision doesn't require abandoning your current treatment progress — a well-documented dose and titration history transfers cleanly to a new prescriber in most cases, and the switch itself typically takes no longer than a standard new-patient intake.
Hims vs Luma Health: Full Semaglutide Comparison
| Factor | Hims | Luma Health |
|---|---|---|
| Compounded semaglutide | Uncertain — verify directly | ✓ $197/mo flat |
| Brand Wegovy/Ozempic (self-pay) | ~$299/mo | N/A — compounded only |
| Compounded tirzepatide | Discontinued | ✓ $297/mo flat |
| Brand Zepbound (self-pay) | ~$1,899/mo | N/A — compounded only |
| Pharmacy named publicly | Not prominently | ✓ VialsRX TX#35264 |
| Video consultations | Not offered for GLP-1 | Not offered |
| Insurance (compounded) | No — cash-pay only | No — cash-pay only |
| Clinical entity | Hims Medical Group | Wasef Health, PC |
Hims vs the Broader Telehealth Semaglutide Market
| Provider | Model | Pharmacy Named |
|---|---|---|
| Henry Meds | Compounded, verify current sema pricing directly | No |
| Hims | Compounded uncertain; brand Wegovy ~$299/mo | No |
| ★ Luma Health | $197/mo flat, compounded, stable | ✓ VialsRX TX#35264 |
| Ro Body | ~$149/mo fee + medication (compounded sema uncertain for new patients) | Ro-owned |
The compounded GLP-1 telehealth market shifted substantially in 2026, with several major platforms — including Hims — moving away from compounded semaglutide and tirzepatide as branded supply stabilized and manufacturer relationships evolved. Luma Health's compounded model has remained stable at $197/month flat for semaglutide throughout these changes, with no supply disruption or product-line restructuring affecting patients during this period.
What Hims' Scale Buys You — and What It Doesn't
It's worth acknowledging Hims' genuine strengths honestly rather than presenting this purely as a cautionary story. As a publicly traded company (NYSE: HIMS) with substantial marketing reach and operational scale, Hims offers a level of brand recognition and platform polish that smaller, specialized GLP-1 telehealth providers often can't match. Onboarding is typically fast, the app experience is well-designed, and for patients who are also interested in Hims' other product categories — hair loss, sexual health, skincare — a single account across multiple health concerns has real convenience value.
What that scale doesn't automatically buy you is stability of any single program within that broader business. Hims operates dozens of product lines simultaneously, and strategic shifts in one category — like the 2026 pivot away from compounded semaglutide — happen at a corporate level based on considerations that go well beyond any individual patient's treatment continuity. A smaller, GLP-1-focused platform has more concentrated incentive to keep that specific offering stable, simply because it represents a larger share of the business rather than one line among many.
Neither model is universally better. Patients who value broad platform access across multiple health categories, and who are comfortable adapting if a specific program changes, may find Hims' overall ecosystem worth the trade-off. Patients whose primary concern is uninterrupted, predictable GLP-1 access specifically may be better served by a platform where that's the core, undiluted business rather than one line item among dozens of product categories competing for the same operational attention.
Brand vs Compounded: Understanding Your Options Now
With Hims' shift toward branded products, it's worth understanding the actual difference between the two pathways rather than treating "brand" and "compounded" as simple better-or-worse categories. Brand-name Wegovy and Ozempic are FDA-approved finished drug products manufactured by Novo Nordisk under strict quality controls, sold in pre-filled injector pens. Compounded semaglutide, prepared by a licensed 503A pharmacy per individual prescription, contains the same active pharmaceutical ingredient but is not itself FDA-approved as a finished product — though the underlying molecule is the same one studied in the STEP trials.
The practical trade-off is largely about cost and delivery format. Brand-name products typically cost significantly more without insurance coverage but come with manufacturer quality assurance and, for many patients, potential insurance coverage or manufacturer savings cards. Compounded medication is typically less expensive for cash-pay patients but depends entirely on the individual compounding pharmacy's quality standards — which is exactly why verifying the specific pharmacy's name and state board license matters so much when evaluating any compounded provider.
Before enrolling with Hims or any provider in transition, take a few minutes to verify three things directly: what specific product you'll actually be prescribed (compounded semaglutide, brand Wegovy, or brand Ozempic), the exact current monthly cost for that specific product, and — if compounded — the name and state board license number of the pharmacy preparing it. None of these should require more than a direct question to support, and a provider that can't answer clearly is worth treating with extra caution regardless of brand recognition.
Compounded, stable, flat-rate.
$197/mo, no disruption.
VialsRX (TX #35264) — independently verifiable. Wasef Health, PC. No contracts.
Start With Luma Health →Frequently Asked Questions
Availability is uncertain following a 2026 dispute with Novo Nordisk that was settled in March 2026. Hims is transitioning toward branded Wegovy/Ozempic (~$299/month self-pay). Verify current compounded semaglutide availability directly at hims.com before enrolling.
It depends on what Hims currently offers you. If compounded semaglutide is still available to you at a legacy rate, compare it directly against Luma Health's $197/month flat. If you're being offered only brand Wegovy/Ozempic at ~$299/month, Luma Health's compounded rate is meaningfully less expensive.
Hims has not prominently disclosed its specific 503A compounding pharmacy in consumer-facing materials. Contact Hims support directly and ask for the pharmacy's name and state board license number. For comparison, Luma Health publicly names VialsRX (TX #35264), verifiable at pharmacy.texas.gov.
Both platforms' compounded semaglutide offerings have changed in 2026 and should be verified directly. Ro's actual billing separates a ~$149/month membership fee from medication cost. Ro offers insurance navigation for brand Wegovy, which Hims doesn't provide in the same way.
Yes. Start Luma Health's intake with your current dose while you still have medication remaining. Wasef Health, PC prescribes at your current dose — no re-titration. Wait for VialsRX shipping confirmation before canceling Hims.
There's no way to know with certainty — this depends on Hims' ongoing supply relationships and the broader regulatory environment for compounded GLP-1 medications, both of which continue to evolve. If continued access to compounded semaglutide specifically is important to your treatment plan, it's more reliable to choose a platform where that's the stable primary offering rather than waiting to see whether a disrupted program is restored.
Possibly, depending on your specific plan — Hims' ~$299/month figure is the self-pay rate for patients without applicable coverage. If your commercial insurance covers Wegovy for a weight-loss indication, your out-of-pocket cost could be substantially lower with prior authorization. Confirm your plan's specific formulary and PA requirements directly with your insurer.
Hims discontinued compounded tirzepatide entirely as part of its 2026 restructuring, now offering only brand-name Zepbound at approximately $1,899/month. Patients specifically wanting compounded tirzepatide will need a different provider — Luma Health offers it at $297/month flat, with no indication that this offering is being phased out.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed 33567185
- FDA. Human Drug Compounding — Section 503A. FDA.gov
- Hims & Hers Health. Weight Loss Program. hims.com
- Texas State Board of Pharmacy. License Verification. pharmacy.texas.gov
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov